GLUD1 and Hyperammonemia: Diazoxide can significantly improve the hypoglycemic symptoms of HHS patients [26], but it cannot effectively control hyperammonemia and some neurological damage in the patients because its target of action is the KATP channel and not the GDH or glutamate metabolic pathway.